Compare SACH & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | SER |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 42.0M |
| IPO Year | 2017 | 2018 |
| Metric | SACH | SER |
|---|---|---|
| Price | $1.05 | $3.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 150.4K | 20.3K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 19.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,906,000.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $3.55 |
| 52 Week High | $1.65 | $7.92 |
| Indicator | SACH | SER |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 48.89 |
| Support Level | $0.96 | $3.68 |
| Resistance Level | $1.08 | $4.12 |
| Average True Range (ATR) | 0.05 | 0.30 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 53.85 | 67.71 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.